Elsevier

Neurobiology of Aging

Volume 34, Issue 6, June 2013, Pages 1530-1539
Neurobiology of Aging

Regular article
A ketone ester diet exhibits anxiolytic and cognition-sparing properties, and lessens amyloid and tau pathologies in a mouse model of Alzheimer's disease

https://doi.org/10.1016/j.neurobiolaging.2012.11.023Get rights and content

Abstract

Alzheimer's disease (AD) involves progressive accumulation of amyloid β-peptide (Aβ) and neurofibrillary pathologies, and glucose hypometabolism in brain regions critical for memory. The 3xTgAD mouse model was used to test the hypothesis that a ketone ester–based diet can ameliorate AD pathogenesis. Beginning at a presymptomatic age, 2 groups of male 3xTgAD mice were fed a diet containing a physiological enantiomeric precursor of ketone bodies (KET) or an isocaloric carbohydrate diet. The results of behavioral tests performed at 4 and 7 months after diet initiation revealed that KET-fed mice exhibited significantly less anxiety in 2 different tests. 3xTgAD mice on the KET diet also exhibited significant, albeit relatively subtle, improvements in performance on learning and memory tests. Immunohistochemical analyses revealed that KET-fed mice exhibited decreased deposition in the subiculum, CA1 and CA3 regions of the hippocampus, and the amygdala. KET-fed mice exhibited reduced levels of hyperphosphorylated tau deposition in the same regions of the hippocampus, amygdala, and cortex. Thus, a novel ketone ester can ameliorate proteopathic and behavioral deficits in a mouse AD model.

Introduction

By 2050, the number of patients with Alzheimer's disease (AD) in the United States is expected to approach 13 million (Thies and Bleiler, 2011). Although there have been advances in the diagnosis of probable AD (McKhann et al., 2011), all clinical trials of interventions aimed at slowing disease progression in patients with mild cognitive impairment (MCI) and AD have failed (Feldman et al., 2007, Petersen et al., 2005, Winblad et al., 2008). The self-aggregation and accumulation of extracellular amyloid β-peptide (Aβ) and intracellular hyperphosphorylated tau (pTau) with cognitive impairment are defining features of AD (Selkoe, 1997). Although mutations in the β-amyloid precursor protein (APP) and the APP-cleaving enzyme presenilin-1 cause rare cases of early-onset familial AD (Bertram et al., 2010), most cases of AD occur after the age of 65 years and have no known cause.

Increasing evidence suggests a role for a chronic positive energy balance resulting from excessive caloric intake and a sedentary lifestyle (and associated insulin resistance) during midlife as AD risk factors (Kapogiannis and Mattson, 2011, Xu et al., 2011). Aβ pathology and cognitive deficits are exacerbated by a high-fat diet (Julien et al., 2010) and diabetes (Takeda et al., 2010), and are ameliorated by dietary energy restriction (Halagappa et al., 2007, Patel et al., 2005, Wang et al., 2005) in mouse models of AD. Moreover, pilot clinical studies have reported improvement in cognitive function and reduced progression of hypometabolism assessed by fluorodeoxyglucose (FDG) positron emission tomography (PET) in patients with AD after intranasal administration of insulin (Craft et al., 2012).

Ketone bodies are an alternative fuel for brain cells when glucose availability is insufficient. The neuroprotective potential of ketones is supported by the well-known efficacy of fasting and ketogenic diets in the treatment of epilepsy (Conklin, 1922, Wilder, 1921). The metabolism of ketone bodies mimics some actions of insulin (Sato et al., 1995) and can overcome insulin resistance (Kashiwaya et al., 1997), suggesting a potential therapeutic benefit of ketone bodies in AD (Kashiwaya et al., 2000). Consistent with the latter possibility, intermittent energy restriction increases levels of circulating β-hydroxybutyrate (Johnson et al., 2007) and ameliorates cognitive impairment in a mouse model of AD (Halagappa et al., 2007).

A ketogenic diet decreased Aβ levels in the brain of AD mice (Van Der Auwera et al., 2005), suggesting that ketone bodies might suppress the pathogenic processes associated with cognitive impairment in AD. However, the latter study did not evaluate the therapeutic potential of ketone bodies per se, and it is not known if ketone bodies can ameliorate behavioral deficits in AD models. There have been no published reports of ketone bodies improving behavioral function and decreasing progression of Aβ and pTau pathologies in AD models. In this study, a novel ketone ester comprised of d-β-hydroxybutyrate and (R)-1,3-butanediol, a precursor of the physiological forms of ketone bodies, was used. The impact of the ketone ester–based diet on the progression of AD-like Aβ and pTau pathologies and behavioral abnormalities in the triple transgenic mouse model of AD, 3xTgAD mice, was examined (Oddo et al., 2003).

Section snippets

Animals, diet, and study overview

The initial generation and characterization of 3xTgAD mice have been reported previously (Oddo et al., 2003). The mice used in the present study were from a colony that had been backcrossed onto a C57BL/6 genetic background for 8 generations and characterized in our previous studies (Liu et al., 2010, Romberg et al., 2011, Rothman et al., 2012). Mice were housed at the National Institute on Aging Biomedical Research Center in Baltimore, MD. Thirty male 3xTgAD mice were housed in groups of 2 to

3xTgAD mice fed a KET diet exhibit a lower average body weight and a higher β-hydroxybutyrate concentration

During the first 50 days on the experimental diets, the mice in both the KET and control (CHO) diet groups exhibited fluctuations in body weight as they adapted to the diets (Fig. 1). Thereafter, the mice on the KET diet maintained body weight approximately 10% to 12% lower than the body weight of mice in the CHO group (KET 38.0 ± 0.7 g, CHO 42.6 ± 1.9 g). There was no difference in the body weight of mice assigned to each group at the time of diet initiation (KET 38.8 g, CHO 37.9 g). Levels of

Discussion

A diet containing a specific ketone ester was found to ameliorate behavioral abnormalities (anxiety and memory deficits) and reduce the amounts of Aβ and pTau in brain regions known to mediate those behaviors in 3xTgAD mice. Previous studies have demonstrated a positive association between levels of endogenous ketone bodies and cognitive function in human subjects and animal models (see Maalouf et al., 2009 for a review). In addition, dietary interventions that increase levels of ketone bodies,

Disclosure statement

The authors declare no competing financial interests.

Acknowledgement

The authors thank Andrew Holmes, Elizabeth Gratton, and Shireesh Srivastava for scientific advice and technical assistance. This research was supported by the Intramural Research Programs of the National Institute on Aging and the National Institute on Alcohol Abuse and Alcoholism.

References (52)

  • Y. Kashiwaya et al.

    A ketone ester diet increases brain malonyl-CoA and uncoupling proteins 4 and 5 while decreasing food intake in the normal Wistar rat

    J. Biol. Chem.

    (2010)
  • M. Maalouf et al.

    The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies

    Brain Res. Rev.

    (2009)
  • M. Maalouf et al.

    Ketones inhibit mitochondrial production of reactive oxygen species production following glutamate excitotoxicity by increasing NADH oxidation

    Neuroscience

    (2007)
  • G.M. McKhann et al.

    The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

    Alzheimers Dement.

    (2011)
  • R.L. Nelson et al.

    Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice

    Exp. Neurol.

    (2007)
  • R.M. Nicholson et al.

    Regional cerebral glucose uptake in the 3xTG model of Alzheimer's disease highlights common regional vulnerability across AD mouse models

    Brain Res.

    (2010)
  • S. Oddo et al.

    Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction

    Neuron

    (2003)
  • N.V. Patel et al.

    Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models

    Neurobiol. Aging

    (2005)
  • P.G. Reeves et al.

    AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet

    J. Nutr.

    (1993)
  • L.M. Refolo et al.

    Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model

    Neurobiol. Dis.

    (2000)
  • M.A. Reger et al.

    Effects of beta-hydroxybutyrate on cognition in memory-impaired adults

    Neurobiol. Aging

    (2004)
  • R. Sterniczuk et al.

    Characterization of the 3xTg-AD mouse model of Alzheimer's disease: part 2. Behavioral and cognitive changes

    Brain Res.

    (2010)
  • P. Tremml et al.

    Neurobehavioral development, adult openfield exploration and swimming navigation learning in mice with a modified beta-amyloid precursor protein gene

    Behav. Brain Res.

    (1998)
  • S. Aznar et al.

    Depression and Alzheimer's disease: is stress the initiating factor in a common neuropathological cascade?

    J. Alzheimers Dis.

    (2011)
  • J.M. Bessa et al.

    A trans-dimensional approach to the behavioral aspects of depression

    Front. Behav. Neurosci.

    (2009)
  • A.J. Bruce-Keller et al.

    Food restriction reduces brain damage and improves behavioral outcome following excitotoxic and metabolic insults

    Ann. Neurol.

    (1999)
  • Cited by (260)

    View all citing articles on Scopus

    Current affiliation: Christian Bergman is a student at University of Virginia School of Medicine.

    The first 2 authors contributed equally to this project.

    View full text